776 related articles for article (PubMed ID: 15906381)
1. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
2. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
3. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse.
Chassain C; Bielicki G; Durand E; Lolignier S; Essafi F; Traoré A; Durif F
J Neurochem; 2008 May; 105(3):874-82. PubMed ID: 18088356
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
5. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
6. Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Dervan AG; Meshul CK; Beales M; McBean GJ; Moore C; Totterdell S; Snyder AK; Meredith GE
Exp Neurol; 2004 Nov; 190(1):145-56. PubMed ID: 15473988
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Meshul CK; Allen C
Synapse; 2000 May; 36(2):129-42. PubMed ID: 10767060
[TBL] [Abstract][Full Text] [Related]
8. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
10. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Jourdain S; Morissette M; Morin N; Di Paolo T
J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
[TBL] [Abstract][Full Text] [Related]
11. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
12. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
Callier S; Morissette M; Grandbois M; PĂ©laprat D; Di Paolo T
Synapse; 2001 Aug; 41(2):131-8. PubMed ID: 11400179
[TBL] [Abstract][Full Text] [Related]
14. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
[TBL] [Abstract][Full Text] [Related]
15. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
Quinn LP; Perren MJ; Brackenborough KT; Woodhams PL; Vidgeon-Hart M; Chapman H; Pangalos MN; Upton N; Virley DJ
J Neurosci Methods; 2007 Aug; 164(1):43-9. PubMed ID: 17498809
[TBL] [Abstract][Full Text] [Related]
16. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
17. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
18. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
[TBL] [Abstract][Full Text] [Related]
19. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function.
Robinson S; Freeman P; Moore C; Touchon JC; Krentz L; Meshul CK
Exp Neurol; 2003 Mar; 180(1):74-87. PubMed ID: 12668150
[TBL] [Abstract][Full Text] [Related]
20. High and low responders to novelty show differential effects in striatal glutamate.
Shakil SS; Holmer HK; Moore C; Abernathy AT; Jakowec MW; Petzinger GM; Meshul CK
Synapse; 2005 Dec; 58(3):200-7. PubMed ID: 16138315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]